Epidemiology and burden of influenza in healthy children aged 6 to 35 months: analysis of data from the placebo arm of a phase III efficacy trial

Abstract Background Despite World Health Organization recommendations, in many countries young children are not targeted for influenza vaccination. To help inform influenza vaccination policy, we examined the occurrence and burden of influenza in healthy children aged 6 to 35 months using data from...

Full description

Bibliographic Details
Main Authors: Clotilde El Guerche-Séblain, Annick Moureau, Camille Schiffler, Martin Dupuy, Stephanie Pepin, Sandrine I. Samson, Philippe Vanhems, François Schellevis
Format: Article
Language:English
Published: BMC 2019-04-01
Series:BMC Infectious Diseases
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12879-019-3920-8
id doaj-ed68e6655d374922b6e05ca7e914f827
record_format Article
spelling doaj-ed68e6655d374922b6e05ca7e914f8272020-11-25T03:47:13ZengBMCBMC Infectious Diseases1471-23342019-04-011911610.1186/s12879-019-3920-8Epidemiology and burden of influenza in healthy children aged 6 to 35 months: analysis of data from the placebo arm of a phase III efficacy trialClotilde El Guerche-Séblain0Annick Moureau1Camille Schiffler2Martin Dupuy3Stephanie Pepin4Sandrine I. Samson5Philippe Vanhems6François Schellevis7Global Vaccine and Epidemiology Department, Sanofi PasteurGlobal Clinical Biostatistics Department, Sanofi PasteurGlobal HEOR Department, Sanofi PasteurGlobal Biostatistics Department, Sanofi PasteurGlobal Clinical Sciences, Sanofi PasteurGlobal Medical Affairs, Sanofi PasteurEpidemiology and International Health Team, Emergent Pathogens Laboratory, Fondation Mérieux, International Center for Research in Infectiology, National Institute of Health and Medical Research, U1111, National Center of Scientific Research, Mixed Scientific Unit 5308, École Nationale Supérieure de Lyon, Université Claude Bernard Lyon 1Netherlands Institute for Health Services ResearchAbstract Background Despite World Health Organization recommendations, in many countries young children are not targeted for influenza vaccination. To help inform influenza vaccination policy, we examined the occurrence and burden of influenza in healthy children aged 6 to 35 months using data from a recent phase III placebo-controlled influenza vaccine trial conducted in countries in the Northern and Southern Hemispheres. Methods This was an analysis of data from participants included in the placebo arm of a phase III clinical trial in healthy children aged 6 to 35 months (EudraCT no. 2013–001231-51). Included children had never been vaccinated for influenza and were observed for one influenza season. Outcome measures included the occurrence of influenza-like illness (ILI), laboratory-confirmed influenza, virus types/subtypes, severe symptoms and complications of confirmed influenza, and healthcare use associated with confirmed influenza. Results Data from 2210 participants were analysed. ILI was reported for 811 participants (36.7%). Of these, 255 participants (31.4%) had 263 virologically confirmed episodes of influenza. The overall influenza attack rate was 11.5%. The most common influenza virus detected was A(H3N2) (40.7%), followed by B/Yamagata (23.6%), A(H1N1) (18.6%), and B/Victoria (8.0%). Grade 3 fever was reported in 24.3% of confirmed episodes, acute lower respiratory infection in 8.7%, acute otitis media in 6.1%, and pneumonia in 1.9%. In most influenza episodes (93.2%), antipyretics, analgesics, or non-steroidal anti-inflammatory drugs were taken. Antibiotics were prescribed for 41.4% of influenza episodes. More than half of the influenza episodes (57.0%) resulted in outpatient visits. Influenza resulted in overnight hospitalisation in 1.1% of episodes. Conclusions Influenza is associated with a significant burden of disease in healthy children. This analysis also revealed that antibiotics continue to be frequently used for young children with influenza. Trial registration EudraCT no. 2013–001231-51.http://link.springer.com/article/10.1186/s12879-019-3920-8InfluenzaChildrenFeverHospitalisationEpidemiologyClinical trial
collection DOAJ
language English
format Article
sources DOAJ
author Clotilde El Guerche-Séblain
Annick Moureau
Camille Schiffler
Martin Dupuy
Stephanie Pepin
Sandrine I. Samson
Philippe Vanhems
François Schellevis
spellingShingle Clotilde El Guerche-Séblain
Annick Moureau
Camille Schiffler
Martin Dupuy
Stephanie Pepin
Sandrine I. Samson
Philippe Vanhems
François Schellevis
Epidemiology and burden of influenza in healthy children aged 6 to 35 months: analysis of data from the placebo arm of a phase III efficacy trial
BMC Infectious Diseases
Influenza
Children
Fever
Hospitalisation
Epidemiology
Clinical trial
author_facet Clotilde El Guerche-Séblain
Annick Moureau
Camille Schiffler
Martin Dupuy
Stephanie Pepin
Sandrine I. Samson
Philippe Vanhems
François Schellevis
author_sort Clotilde El Guerche-Séblain
title Epidemiology and burden of influenza in healthy children aged 6 to 35 months: analysis of data from the placebo arm of a phase III efficacy trial
title_short Epidemiology and burden of influenza in healthy children aged 6 to 35 months: analysis of data from the placebo arm of a phase III efficacy trial
title_full Epidemiology and burden of influenza in healthy children aged 6 to 35 months: analysis of data from the placebo arm of a phase III efficacy trial
title_fullStr Epidemiology and burden of influenza in healthy children aged 6 to 35 months: analysis of data from the placebo arm of a phase III efficacy trial
title_full_unstemmed Epidemiology and burden of influenza in healthy children aged 6 to 35 months: analysis of data from the placebo arm of a phase III efficacy trial
title_sort epidemiology and burden of influenza in healthy children aged 6 to 35 months: analysis of data from the placebo arm of a phase iii efficacy trial
publisher BMC
series BMC Infectious Diseases
issn 1471-2334
publishDate 2019-04-01
description Abstract Background Despite World Health Organization recommendations, in many countries young children are not targeted for influenza vaccination. To help inform influenza vaccination policy, we examined the occurrence and burden of influenza in healthy children aged 6 to 35 months using data from a recent phase III placebo-controlled influenza vaccine trial conducted in countries in the Northern and Southern Hemispheres. Methods This was an analysis of data from participants included in the placebo arm of a phase III clinical trial in healthy children aged 6 to 35 months (EudraCT no. 2013–001231-51). Included children had never been vaccinated for influenza and were observed for one influenza season. Outcome measures included the occurrence of influenza-like illness (ILI), laboratory-confirmed influenza, virus types/subtypes, severe symptoms and complications of confirmed influenza, and healthcare use associated with confirmed influenza. Results Data from 2210 participants were analysed. ILI was reported for 811 participants (36.7%). Of these, 255 participants (31.4%) had 263 virologically confirmed episodes of influenza. The overall influenza attack rate was 11.5%. The most common influenza virus detected was A(H3N2) (40.7%), followed by B/Yamagata (23.6%), A(H1N1) (18.6%), and B/Victoria (8.0%). Grade 3 fever was reported in 24.3% of confirmed episodes, acute lower respiratory infection in 8.7%, acute otitis media in 6.1%, and pneumonia in 1.9%. In most influenza episodes (93.2%), antipyretics, analgesics, or non-steroidal anti-inflammatory drugs were taken. Antibiotics were prescribed for 41.4% of influenza episodes. More than half of the influenza episodes (57.0%) resulted in outpatient visits. Influenza resulted in overnight hospitalisation in 1.1% of episodes. Conclusions Influenza is associated with a significant burden of disease in healthy children. This analysis also revealed that antibiotics continue to be frequently used for young children with influenza. Trial registration EudraCT no. 2013–001231-51.
topic Influenza
Children
Fever
Hospitalisation
Epidemiology
Clinical trial
url http://link.springer.com/article/10.1186/s12879-019-3920-8
work_keys_str_mv AT clotildeelguercheseblain epidemiologyandburdenofinfluenzainhealthychildrenaged6to35monthsanalysisofdatafromtheplaceboarmofaphaseiiiefficacytrial
AT annickmoureau epidemiologyandburdenofinfluenzainhealthychildrenaged6to35monthsanalysisofdatafromtheplaceboarmofaphaseiiiefficacytrial
AT camilleschiffler epidemiologyandburdenofinfluenzainhealthychildrenaged6to35monthsanalysisofdatafromtheplaceboarmofaphaseiiiefficacytrial
AT martindupuy epidemiologyandburdenofinfluenzainhealthychildrenaged6to35monthsanalysisofdatafromtheplaceboarmofaphaseiiiefficacytrial
AT stephaniepepin epidemiologyandburdenofinfluenzainhealthychildrenaged6to35monthsanalysisofdatafromtheplaceboarmofaphaseiiiefficacytrial
AT sandrineisamson epidemiologyandburdenofinfluenzainhealthychildrenaged6to35monthsanalysisofdatafromtheplaceboarmofaphaseiiiefficacytrial
AT philippevanhems epidemiologyandburdenofinfluenzainhealthychildrenaged6to35monthsanalysisofdatafromtheplaceboarmofaphaseiiiefficacytrial
AT francoisschellevis epidemiologyandburdenofinfluenzainhealthychildrenaged6to35monthsanalysisofdatafromtheplaceboarmofaphaseiiiefficacytrial
_version_ 1724502943505317888